Aktienanalyse zu Structure Therapeutics Inc (GPCR)GPCRStructure Therapeutics Inc

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Structure Therapeutics Inc (GPCR) is currently priced at $47.37, which is significantly lower than the analyst price target of $111 from Canaccord. However, the stock has a low RSI of 22.854, indicating it is oversold, but it also has a negative forward P/E ratio of 0, suggesting uncertainty about future earnings. The main risk is the declining net income, with a loss of $106,159,000 reported in Q2 2026, which raises concerns about the company's financial health.